SUSMED Insomnia Therapeutic App and DTx Platform

SUSMED, Inc. is a Tokyo-based digital therapeutics company listed on the Tokyo Stock Exchange Growth Market and led by CEO Taro Ueno. It started as a limited liability company in 2015 and was incorporated in 2016, aiming to make healthcare more sustainable by offering non-drug treatments and lowering the cost of drug development.

Its insomnia treatment app delivers cognitive behavioural therapy on a smartphone under a doctor's management, targeting the thinking patterns and habits behind insomnia; it received marketing approval in Japan in 2023 and insurance coverage from June 2026. SUSMED also develops apps for breast cancer and kidney disease on its QDTx development platform, and sells the SUSMED System, which uses proprietary blockchain technology to verify clinical trial data for drug developers.

• Insomnia therapeutic app: smartphone CBT for insomnia managed by a physician.
• Regulatory approval: approved medical device in Japan with insurance coverage from June 2026.
• DTx pipeline: apps in development for breast cancer and kidney disease.
• QDTx platform: in-house framework for rapid prototyping and efficacy testing of therapeutic apps.
• SUSMED System: blockchain-based verification of clinical trial data.
• Workplace sleep programmes: seminars linking sleep data to human capital management for employers.

Vietnamese hospitals with sleep or psychiatry clinics could partner on a localised CBT-I app as a non-drug option. Contract research organisations and pharma companies running trials in Vietnam could use blockchain data verification to reduce monitoring visits. Japanese-invested factories in Vietnam could adopt workplace sleep programmes.

Offers clinicians an insurance-covered, non-drug insomnia treatment option in Japan. Lets patients continue therapy without frequent hospital visits and reduces clinician workload. The QDTx platform shortens build-and-test cycles for new therapeutic apps. The SUSMED System removes manual reconciliation of trial data with hospital records, lowering staffing and cost for sponsors.

Japan is one of the first Asian markets to reimburse prescription digital therapeutics, setting a model that other countries in the region are watching. Sleep problems are linked to lower productivity, and Japanese employers increasingly treat sleep as part of health and productivity management. Pharma companies across Asia are also looking for ways to cut the cost of clinical trial monitoring.

Founded as a limited liability company in July 2015 and incorporated in February 2016; HQ in Nihonbashi, Tokyo. Listed on TSE Mothers in 2021, moved to the Growth Market in 2022. Holds ISMS certification and a Class II medical device marketing licence. Alliances with Suzuken, Sumitomo Corporation, Nippon Chemiphar, Sawai Pharmaceutical and CMIC.